BEGIN:VCALENDAR
PRODID:-//AT Content Types//AT Event//EN
VERSION:1.0
BEGIN:VEVENT
DTSTART:20081006T041500Z
DTEND:20081008T041500Z
DCREATED:20080213T211526Z
UID:ATEvent-39dd972488b92e60d4f94424b001a958
SEQUENCE:0
LAST-MODIFIED:20080213T212014Z
SUMMARY:Translational Biomarkers\: Pathways to Phase II Survival
DESCRIPTION:The first ACS ProSpectives conference on translational Bio
 markers will be chaired by Dr. Lisa Gold\, Executive Director of Merck
 \, and Dr. Paul Galatsis\, Associate Research Fellow of Pfizer. Togeth
 er they have gathered a group of highly regarded pharmaceutical indust
 ry and academic scientists who will lecture and present case studies o
 ver the course of the two-and-a half-day program. \n\nThe high attriti
 on rates experienced in Phase II has multiple implications for drug di
 scovery and the pharmaceutical industry in general.  This conference i
 s geared specifically for medicinal chemists and focuses on the pathwa
 ys for developing translational biomarkers. These tools facilitate the
  translation of preclinical candidates into clinical programs with a g
 reater degree of confidence and have the potential to increase the pro
 bability of their success.  \n\nThis program is comprised of three ses
 sions that address key areas of interest for the practicing medicinal 
 chemist.  They are\: \n\n        Translatable target engagement bio
 markers (imaging and non-imaging biomarkers)\n        Mechanism bio
 markers\, including safety\n        Clinical biomarkers\, including
  disease biomarkers and regulatory acceptance\n\nIn each session\, fou
 r speakers will present on their research addressing and providing the
 ir prospective on the session topic. Real life examples will illustrat
 e how the theoretical can be used to address practical issues.
PRIORITY:3
TRANSP:0
END:VEVENT
END:VCALENDAR